--- a
+++ b/clusters/9knumclustersv2/clust_1425.txt
@@ -0,0 +1,32 @@
+At least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+Biologic (anti-neoplastic) agent: at least  days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+Biologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >=  days prior to study enrollment\r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+At least  days must have passed after the last treatment with a biologic agent; for agents that have known adverse events occurring beyond  days from administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+Biologic (anti-neoplastic agent): at least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+At least  days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; these patients must be discussed with the Study Chair or Co-Chair on a case-by-case basis including any patient on a drug with a half-life of >  hours
+At least  days must have elapsed since the completion of therapy with a biologic agent. For biologic agents that have known adverse events occurring beyond  days after administration, the period prior to enrollment must be extended beyond the time during which adverse events are known to occur.
+Biologic agent: patient must have recovered from any toxicity potentially related to the agent and received their last dose of the biologic agent >=  days prior to study registration\r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval should be discussed with the study chair\r\n* For biologic agents that have a prolonged half-life, the appropriate interval since last treatment should be discussed with the study chair prior to registration
+Biologic (anti-neoplastic agent): At least  days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the Study Chair.
+Biologic or investigational agent (anti-neoplastic): Patient must have received their last dose of the investigational or biologic agent >=  days prior to study enrollment \r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration must be discussed with and approved by the study chair\r\n* Monoclonal antibody treatment and/or agents with prolonged half-lives: at least three half-lives must have elapsed prior to enrollment
+INCLUSION CRITERIA FOR STRATUM C: Patient must have received their last dose of the investigational or biologic agent >=  days prior to study enrollment\r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration must be discussed with and approved by the study chair\r\n* Monoclonal antibody treatment and/or agents with prolonged half-lives: at least three half-lives must have elapsed prior to enrollment
+At least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur
+Therapy with biologic agents (non-myelosuppressive) must have been completed >=  days prior to study entry; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; these patients must be discussed with the Study Chair on a case-by-case basis
+At least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur
+Biologic (anti-neoplastic agent): at least  days must have elapsed since the completion of therapy with other biologic agents; for other biologic agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+Biologic (anti-neoplastic agent): At least  days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the Study Chair.
+Biologic agent - must have recovered from any acute toxicity potentially related to the agent and received their last dose of the biologic agent >  days prior to study enrollment\r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+Biologic (anti-neoplastic agent): must not have received within  days of entry onto this study ( days if prior vascular endothelial growth factor (VEGF)-trap and at least  half-lives after last dose of a monoclonal antibody); for biologic agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent such as steroids, retinoids; Note: for agents that have known adverse events occurring beyond  days after administration (i.e. monoclonal antibodies), this period must be extended beyond the time during which acute adverse events are known to occur
+Biologic (anti-neoplastic) agent: at least  days since the completion of therapy with a biologic agent or donor lymphocyte infusions (DLI); for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur
+Biologic (anti-neoplastic agent): at least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+At least  days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
+Subject has had prior treatment with biologic antineoplastic agents less than  days before the first dose of lenalidomide. For agents that have known Adverse Events (AEs) occurring beyond  days after administration (ie, monoclonal antibodies), this period must be extended beyond the time during which acute AEs are known to occur.
+Patients must have received their last dose of any other biologic agent greater than  days prior to enrollment\r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur and discussed with the PI
+Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; these subjects must be discussed with the study chair on a case-by-case basis
+At least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the principal investigator
+Biologic (anti-neoplastic) therapy: It must be at least  days after last does of biologic agent. For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
+Investigational/biologic agent: \r\n* Biologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >=  days prior to study registration \r\n** For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibody treatment and agents with known prolonged half-lives: at least three half-lives must have elapsed prior to registration; Note: a list of the half-lives of commonly used monoclonal antibodies is available on the Pediatric Brain Tumor Consortium (PBTC) webpage under Generic Forms and Templates
+Biologic (anti-neoplastic agent) or metronomic non-myelosuppressive chemotherapy: at least  days must have elapsed since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur
+RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Biologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >=  days prior to study enrollment \r\n* For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur, and discussed with the principal investigator
+At least  days must have passed after the last treatment with a biologic agent; for agents that have known adverse events occurring beyond  days from administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair